Drug Trial Radar · NCT07675785
PfSPZ-LARC2 Vaccine in Women of Child-bearing Potential (WOCBP) in Mali
Last checked: Nov 20, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Jul 20, 2026
Primary completion
Jul 15, 2028
Study completion Apr 2030
Sponsor
- Lead sponsor
- Sanaria Inc.Industry
- Sponsor type
- Industry
- Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID); University of the Sciences, Techniques and Technologies of Bamako; Malaria Research and Training Center, Bamako, Mali
- First posted
- Jun 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 38 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A randomized double blind, placebo-controlled study to assess the safety, tolerability, immunogenicity, and protective efficacy of 1, 6, 29-day PfSPZ-LARC2 Vaccine regimen given at a dose of 2 x10\^5 PfSPZ or placebo in healthy WOCBP, who are on pregnancy prevention during vaccination, but report plans to become pregnant in the near future. Participants will be randomized into two arms. Arm 1: (n= 150) will receive 3 doses of PfSPZ-LARC2 Vaccine (2x10\^5 PfSPZ) via direct venous inoculation (DVI) at 1, 6, 29 days. Arm 2: (n= 150) will receive 3 doses of normal saline (placebo) injection via DVI at 1, 6, 29 days. All volunteers will receive antimalarial treatment with artemether/lumefantrine (AL) \~2 to 4 weeks prior to 1st (study day -14 to -28) and \~2 weeks prior to 3rd injection (study day 44). Participants will be monitored for safety, tolerability, immunogenicity, and malaria infection during the follow-up period. Participants will also be monitored closely for pregnancy as well post 3rd injection through the entire planned study duration (2 years post dose 1). If pregnant, women will be followed during the course of their pregnancy and for at least 1 year post-delivery (as well as their offspring) for safety and malaria infection. Malaria infections in participants and their offspring will be classified as asymptomatic or symptomatic (clinical cases).
Conditions
- Malaria (Plasmodium Falciparum)
Interventions
PfSPZ-LARC2 VaccineBiological
PfSPZ-LARC2 Vaccine (2x105 PfSPZ) via direct venous inoculation (DVI)
Normal SalineOther
Normal Saline
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of local AEsTime frame: Day 1 to Day 35
- Incidence of systemic adverse eventsTime frame: Day 1 to Day 35
- P.falciparum blood stage infection defined as time to first positive P.falciparum blood smear following 3rd injection to over 24 weeksTime frame: Day 29 to 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Sciences, Techniques and Technology, Bamako (USTTB)
Bamako, Mali · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.